积石成山丨中国科学院大学附属肿瘤医院（浙江省肿瘤医院）胸部肿瘤内科张沂平团队临床试验汇总

参与的国内国际临床试验

Lancet Oncol Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study Yi-ping Zhang (2011)

Lancet Oncol Icotinib versus gefitinib in previously treated advanced non-small-cell lung cancer (ICOGEN): a randomised, double-blind phase 3 non-inferiority trial  Yi-ping Zhang (2013)

Thorac Cancer Long-term results of a randomized, double-blind, and placebo-controlled phase III trial: Endostar (rh-endostatin) versus placebo in combination with vinorelbine and cisplatin in advanced non-small cell lung cancer Yi-ping Zhang (2013)

Lung Cancer A single-arm，multicenter，safety-monitoring，phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC) Yi-ping Zhang (2014）

Medicine Erlotinib plus capecitabine as first-line treatment for older Chinese patients with advanced adenocarcinoma of the lung（C-TONG 0807）：an open-label，single arm，multicenter phase II study  Yi-ping Zhang (2015）

Lung Cancer  EGFR mutation prevalence in Asia-Pacific and Russian patients with advanced NSCLC of adenocarcinoma and non-adenocarcinoma histology: The IGNITE study  Yi-ping Zhang (2017)

Br J Cancer  Anlotinib as a third-line therapy in patients with refractory advanced non-small-cell lung cancer: a multicentre, randomised phase II  trial (ALTER0302)  Yi-ping Zhang (2018)

Invest New Drugs  Phase III study of dulanermin (recombinant human tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand) combined with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer  Yi-ping Zhang (2018)

J Thorac Oncol Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial  Yi-ping Zhang (2019)

Lancet Respir Med Alectinib versus crizotinib in untreated Asian patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer (ALESIA): a randomised phase 3 study  Yi-ping Zhang (2019)

Lancet Respir Med Efficacy, safety, and biomarker analysis of ensartinib in crizotinib-resistant, ALK-positive non-small-cell lung cancer: a multicentre, phase 2 trial Yi-ping Zhang (2019)

Lancet Respir Med Tepotinib plus gefitinib in patients with EGFR-mutant non-small-cell lung cancer with MET overexpression or MET amplification and acquired resistance to previous EGFR inhibitor (INSIGHT study): an open-label, phase 1b/2, multicentre, randomised trial  Yi-ping Zhang (2020)

Transl Lung Cancer Res  Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer Yi-ping Zhang (2020)

J Clin Oncol  Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: A multicenter, open-label, single-arm, phase II study  Yi-ping Zhang (2020)

Ann Oncol Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer anopen-label, randomized, multicenter, phase III trial   Yi-ping Zhang (2020)

Lancet Respir Med Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotheray-naive patients with advanced non-squamous non-small-cell lung cancer (CameL) : a randomised, open-label, multicentre, phase 3 trial  Yi-ping Zhang (2020)

Lung Cancer A phase III, randomized, double-blind, placebo-controlled, multicenter study of fruquintinib in Chinese patients with advanced nonsquamous non-small-cell lung cancer-the FALUCA study Yi-ping Zhang (2020)

Lung Cancer Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078) Yi-ping Zhang (2020)

Cancer Final report of a prospective randomized study on thoracic radiotherapy target volume for limited-stage small cell lung cancer with radiation dosimetric analyses  Yi-ping Zhang (2020)

Anticancer Pegylated filgrastim is comparable with filgrastim as support for commonly used chemotherapy regimens：a multicenter，randomized，crossover phase 3 study  Yi-ping Zhang（2013）

Head Neck Platinum-based chemotherapy plus cetuximab first-line for Asian patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck：results of an open-label，single-arm，multicenter trial Yi-ping Zhang（2015）

Lancet Oncol  Camrelizumab versus investigator’s choice of chemotherapy as second-line therapy for advanced or metastatic oesophageal squamous cell carcinoma (ESCORT): a multicentre, randomised, open-label, phase 3 study  Yi-ping Zhang (2020)

Cancer Commun CMAB009 plus irinotecan versus irinotecan‑only as second‑line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild‑type metastatic colorectal cancer patients: promising findings from a prospective, open‑label, randomized, phase III trial  Yi-ping Zhang (2020) 

推荐阅读

肺癌系列文章汇总 (2021年1月)肺癌，临床试验招募汇总NCCN丨非小细胞肺癌临床实践指南2021.2版①NCCN丨非小细胞肺癌临床实践指南2021.2版②

整理者